AAAAAA

   
Results: 1-25 | 26-40 |
Results: 26-40/40
Production of ex vivo expanded hematopoietic cells and progenitors in a closed bioreactor, starting with a small volume marrow collection: A feasibility study in patients with poor-risk breast cancer and receiving high-dosesof cyclophosphamide
Authors: Chabannon, C Blache, JL Sielleur, I Douville, J Faucher, C Gravis, G Arnoulet, C Oziel-Taieb, S Blaise, D Novakovitch, G Camerlo, J Chabbert, I Genre, D Appel, M Armstrong, D Maraninchi, D Viens, P
Citation: C. Chabannon et al., Production of ex vivo expanded hematopoietic cells and progenitors in a closed bioreactor, starting with a small volume marrow collection: A feasibility study in patients with poor-risk breast cancer and receiving high-dosesof cyclophosphamide, INT J ONCOL, 15(3), 1999, pp. 511-518
Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- orsecond-line treatment in advanced malignant melanoma: a trial of the EORTCClinical Studies Group
Authors: Cure, H Souteyrand, P Ouabdesselam, R Roche, H Ravaud, A D'incan, M Viens, P Fargeot, P Lentz, MA Fumoleau, P Hanauske, A Chollet, P
Citation: H. Cure et al., Results of a phase II trial with cystemustine at 90 mg/m(2) as a first- orsecond-line treatment in advanced malignant melanoma: a trial of the EORTCClinical Studies Group, MELANOMA RE, 9(6), 1999, pp. 607-610
Efficacy and safety of docetaxel (Taxotere (TM)) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience
Authors: Bonneterre, J Spielman, M Guastalla, JP Marty, M Viens, P Chollet, P Roche, H Fumoleau, P Mauriac, L Bourgeois, H Namer, M Bergerat, JP Misset, JL Trandafir, L Mahjoubi, M
Citation: J. Bonneterre et al., Efficacy and safety of docetaxel (Taxotere (TM)) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experience, EUR J CANC, 35(10), 1999, pp. 1431-1439
Phase II study of a combination of low-dose cisplatin with 13-cis-retinoicacid and interferon-alpha in patients with advanced head and neck squamouscell carcinoma
Authors: Gravis, G Pech-Gourgh, F Viens, P Alzieu, C Camerlo, J Oziel-Taieb, S Jausseran, M Maraninchi, D
Citation: G. Gravis et al., Phase II study of a combination of low-dose cisplatin with 13-cis-retinoicacid and interferon-alpha in patients with advanced head and neck squamouscell carcinoma, ANTI-CANC D, 10(4), 1999, pp. 369-374
Patients who are receiving concomitant medications should not systematically be excluded from phase I studies
Authors: Genre, D Viens, P Von Hoff, DD Clark, GM
Citation: D. Genre et al., Patients who are receiving concomitant medications should not systematically be excluded from phase I studies, ANTI-CANC D, 10(1), 1999, pp. 1-7
HIV infection among pregnant women in Bobo-Dioulasso, Burkina Faso: comparison of voluntary and blinded seroprevalence estimates
Authors: Meda, N Zoundi-Guigui, MT van de Perre, P Alary, M Ouangre, A Cartoux, M Mandelbrot, L Viens, P Dabis, F
Citation: N. Meda et al., HIV infection among pregnant women in Bobo-Dioulasso, Burkina Faso: comparison of voluntary and blinded seroprevalence estimates, INT J STD A, 10(11), 1999, pp. 738-740
Cytokines in metastatic renal cell carcinoma: Is it useful to switch to interleukin-2 or interferon after failure of a first treatment?
Authors: Escudier, B Chevreau, C Lasset, C Douillard, JY Ravaud, A Fabbro, M Caty, A Rossi, JF Viens, P Bergerat, JP Savary, J Negrier, S
Citation: B. Escudier et al., Cytokines in metastatic renal cell carcinoma: Is it useful to switch to interleukin-2 or interferon after failure of a first treatment?, J CL ONCOL, 17(7), 1999, pp. 2039-2043
CD34(+) cell enumeration in peripheral blood and apheresis samples, using two laboratory diagnostic kits or an institutional protocol
Authors: Olivero, S Alario, T Ladaique, P Haccoun, M Viens, P Blaise, D Chabannon, C
Citation: S. Olivero et al., CD34(+) cell enumeration in peripheral blood and apheresis samples, using two laboratory diagnostic kits or an institutional protocol, BONE MAR TR, 23(4), 1999, pp. 387-394
High-dose chemotherapy with hematopoietic stem cell support in patients with advanced epithelial ovarian cancer: Analysis of 67 patients treated in asingle institution
Authors: Bertucci, F Viens, P Gravis, G Blaise, D Faucher, C Oziel-Taoeb, S Bardou, VJ Jacquemier, J Delpero, JR Maraninchi, D
Citation: F. Bertucci et al., High-dose chemotherapy with hematopoietic stem cell support in patients with advanced epithelial ovarian cancer: Analysis of 67 patients treated in asingle institution, ANTICANC R, 19(2B), 1999, pp. 1455-1461
Peritumoral vascular invasion in women with node-negative breast cancer, receiving no adjuvant therapy
Authors: Mathoulin-Portier, MP Meynard, P Charton-Bain, MC Escoute, M Bardou, VJ Puig, B Viens, P Cowen, D Houvenaeghel, G Hassoun, J Jacquemier, J
Citation: Mp. Mathoulin-portier et al., Peritumoral vascular invasion in women with node-negative breast cancer, receiving no adjuvant therapy, ANTICANC R, 19(1B), 1999, pp. 843-847
Association of angiogenesis and poor prognosis in node-positive patients receiving anthracycline-based adjuvant chemotherapy
Authors: Viens, P Jacquemier, J Bardou, VJ Bertucci, F Penault-Llorca, F Puig, B Gravis, G Oziel-Taieb, S Resbeut, M Houvenaeghel, G Camerlo, J Birbaum, D Hassoun, J Maraninchi, D
Citation: P. Viens et al., Association of angiogenesis and poor prognosis in node-positive patients receiving anthracycline-based adjuvant chemotherapy, BREAST CANC, 54(3), 1999, pp. 205-212
Concomitant chemoradiotherapy for patients with nonmetastatic breast carcinoma - Side effects, quality of life, and daily organization
Authors: Macquart-Moulin, G Viens, P Genre, D Bouscary, ML Resbeut, M Gravis, G Camerlo, J Maraninchi, D Moatti, JP
Citation: G. Macquart-moulin et al., Concomitant chemoradiotherapy for patients with nonmetastatic breast carcinoma - Side effects, quality of life, and daily organization, CANCER, 85(10), 1999, pp. 2190-2199
First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial)
Authors: Viens, P Palangie, T Janvier, M Fabbro, M Roche, H Delozier, T Labat, JP Linassier, C Audhuy, B Feuilhade, F Costa, B Delva, R Cure, H Rousseau, F Guillot, A Mousseau, M Ferrero, JM Bardou, VJ Jacquemier, J Pouillart, P
Citation: P. Viens et al., First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial), BR J CANC, 81(3), 1999, pp. 449-456
A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia
Authors: Maraninchi, D Vey, N Viens, P Stoppa, AM Archimbaud, E Attal, M Baume, D Bouabdallah, R Demeoq, F Fleury, J Michallet, M Olive, D Reiffers, J Sainty, D Tabilio, A Tiberghien, P Brandely, M Hercend, T Blaise, D
Citation: D. Maraninchi et al., A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemia, LEUK LYMPH, 31(3-4), 1998, pp. 343-349
rIL-2 in metastatic soft tissue sarcomas refractory to chemotherapy: Response and enhancement of further chemosensitivity
Authors: Gravis, G Viens, P Delva, R Baume, D Blaise, D Ternier, F Houvenaeghel, G Brandely, M Resbeut, M Maraninchi, D
Citation: G. Gravis et al., rIL-2 in metastatic soft tissue sarcomas refractory to chemotherapy: Response and enhancement of further chemosensitivity, ANTICANC R, 18(5B), 1998, pp. 3699-3704
Risultati: 1-25 | 26-40 |